Speaker illustration

Doctor Ophelia Qiping Yin

Daiichi Sankyo Pharma Development, Edison, New Jersey (United States of America)

Linking intrinsic factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial

Event: ESC CONGRESS 2016

Topic: Atrial fibrillation (AF)

Session: New trends in antithrombotic therapy for atrial fibrillation

Thumbnail

ESC 365 is supported by

logo Novo Nordisk